Jason Rickard - 08 Mar 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Reporting relationship: SVP, Chief Operating Officer
Issuer ticker: IRWD
Reported as of: 08 Mar 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Mar 2023, 16:12:10 UTC
Prior SEC filing: 01 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian Tessler, Attorney-in-Fact

Key filing fact

Jason Rickard filed Form 4 for IRONWOOD PHARMACEUTICALS INC (IRWD) on 10 Mar 2023.

Key facts

This page summarizes Jason Rickard's Form 4 filing for IRONWOOD PHARMACEUTICALS INC (IRWD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2023, 16:12.

Change

Previous filing in this sequence was filed on 01 Mar 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRWD transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +43,668
Change %: +13%
Price: $0.000000
Shares after: 376,316
Date: 08 Mar 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRWD transaction Derivative

Performance-based Restricted Stock Units

Award

Transaction value: $0
Shares: +21,834
Change %
Price: $0.000000
Shares after: 21,834
Date: 08 Mar 2023
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 21,834
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.

Footnote F2

Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share.